Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $18,804 | $10,937 | $10,400 | $50,223 |
| - Cash | $0 | $7,004 | $12,445 | $30,018 |
| + Debt | $0 | $1,058 | $255 | $2,632 |
| Enterprise Value | $18,804 | $4,991 | -$1,790 | $22,837 |
| Revenue | $186 | $102 | $0 | $0 |
| % Growth | 82.4% | – | – | – |
| Gross Profit | $174 | $33 | -$1,440 | -$1,520 |
| % Margin | 93.5% | 32.4% | – | – |
| EBITDA | -$5,687 | -$7,763 | -$39,695 | -$25,414 |
| % Margin | -3,057.5% | -7,610.8% | – | – |
| Net Income | -$5,824 | -$8,448 | -$40,935 | -$26,512 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| Operating Cash Flow | – | -$15,202 | -$28,010 | -$26,643 |
| Capital Expenditures | – | -$899 | -$123 | -$393 |
| Free Cash Flow | – | -$16,101 | -$28,133 | -$27,036 |